Advances in™ Infectious Diseases: Overcoming Fungal Infections: Prophylaxis, Diagnosis, and Treatment Strategies to Improve Patient Outcomes
October 31, 2019
October 31, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
Supported by an educational grant from Astellas.
- Physicians — maximum of 2.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This online educational activity is directed toward primary care physicians, infectious disease specialists, nurse practitioners, and physicians’ assistants who are involved in the treatment of fungal infections.
Invasive fungal infections (IFIs) contribute to substantial morbidity and mortality in immunocompromised individuals. The incidence of these infections is increasing, in part by the growing number of immunocompromised patients, including those with neutropenia, HIV, chronic immunosuppression, diabetes mellitus, hematological malignancies, transplantation, severe burns, and major surgery. Treatment requires early suspicion and is difficult because just a few antifungal agents are available, most agents have adverse effects, and some organisms have developed resistance to antifungal agents. This activity will provide clinicians with insights into IFI incidence and diagnostic methods and the management of these infections.
Benefits of Participating
- Learn about strategic measures to improve on care of patients at risk of invasive IFI, including ways to improve or implement strategies that may reduce the risk
- Increase awareness of treatment measures for patients at risk or those who have acquired these infections within their immunocompromised state
- Learn about best practices to enhance clinical decision making when choosing among treatment options available for patients who need emergent management of IFI
Upon completion of this activity, participants should be able to:
- Identify at-risk populations for IFI and IFI-related complications
- Review effective diagnostic testing for IFI
- Select an individualized plan of care based on current guideline recommendations, including prophylactic therapy in high-risk populations
Peter G. Pappas, MD, FACP
Professor of Medicine
Director, Mycoses Study Group
Division of Infectious Diseases
University of Alabama at Birmingham
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Credit Designation Statement
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Disclosures of Conflicts of Interest
Peter G. Pappas, MD, FACP
- Grant/Research Support: Amplyx, Astellas, Cidara, IMMY, Merck, Scynexis
- Consultant: Amplyx, Cidara, Scynexis
The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
Method of Participation
Instructions for This Activity and Receiving Credit
- You will need to log in to participate in the activity.
- Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
- At the end of the activity, educational content/audio files will be available for your reference.
- In order to receive a CME/CE certificate, you must complete the activity.
- Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER®, as a sponsor accredited by the ACCME, to ensure fair balance, independence, objectivity, and scientific rigor in all its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.